Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 179.6% in December

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 86,400 shares, a growth of 179.6% from the November 30th total of 30,900 shares. Approximately 2.0% of the company’s stock are sold short. Based on an average daily trading volume, of 3,000,000 shares, the short-interest ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC acquired a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path at the end of the most recent quarter. 5.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Bio-Path in a research report on Thursday. They set a “sell” rating on the stock.

Bio-Path Stock Performance

Shares of BPTH traded down $0.21 during midday trading on Friday, hitting $1.14. The company had a trading volume of 491,588 shares, compared to its average volume of 1,509,598. Bio-Path has a 1 year low of $0.59 and a 1 year high of $12.00. The company’s 50-day simple moving average is $0.89 and its 200-day simple moving average is $1.24.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.